
Pharma Report: Inside Eli Lilly’s Move on Insulin
March 7, 2023 Eli Lilly’s decision to lower the list price of its most popular insulin product by 70 percent in the final months of 2023 will save the company millions of dollars it would have paid in rebates to state Medicaid programs starting in 2024, POLITICO’s David Lim reports. State Medicaid programs would have generated about… Read more »